Table 1:
Demographic, clinical and treatment characteristics.
| CNS-Treated Survivors (N=1567) | Non-CNS-Treated Survivors (N=1292) | ||||||
|---|---|---|---|---|---|---|---|
| N (%) | M (SD) | N (%) | M (SD) | ||||
| Age at evaluation, years | 33.0 (8.84) | 36.2 (9.84) | |||||
| Age at diagnosis, years | 7.6 (4.80) | 9.1 (6.33) | |||||
| Time since diagnosis, years | 25.5 (9.05) | 27.1 (9.57) | |||||
| Male | 835 (53.30) | 653 (50.54) | |||||
| Race/Ethnicity | |||||||
| White, non-Hispanic | 1345 (85.83) | 1012 (78.33) | |||||
| Black, non-Hispanic | 185 (11.81) | 258 (19.97) | |||||
| Hispanic | 20 (1.28) | 14 (1.08) | |||||
| Other | 17 (1.08) | 8 (0.62) | |||||
| Diagnosis | |||||||
| Acute lymphoblastic leukemia | 977 (62.35) | 1 (0.08) | |||||
| CNS tumor | 324 (20.68) | 22 (1.70) | |||||
| Ewing sarcoma | 6 (0.38) | 72 (5.57) | |||||
| Hodgkin lymphoma | 6 (0.38) | 330 (25.54) | |||||
| Neuroblastoma | 0 (0.00) | 106 (8.20) | |||||
| Non-Hodgkin lymphoma | 162 (10.34) | 43 (3.33) | |||||
| Osteosarcoma | 2 (0.13) | 119 (9.21) | |||||
| Retinoblastoma | 3 (0.19) | 101 (7.82) | |||||
| Rhabdomyosarcoma | 17 (1.08) | 81 (6.27) | |||||
| Soft tissue sarcoma | 6 (0.38) | 64 (4.95) | |||||
| Wilms tumor | 2 (0.13) | 183 (14.16) | |||||
| Othersa | 62 (3.96) | 170 (13.16) | |||||
| Radiation | |||||||
| Any radiation treatment | 867 (55.33) | 749 (57.97) | |||||
| Cranial radiation (Gy) (yes) | 822 (52.46) | 32.1 (19.4) | |||||
| ≤ 20 | 227 (27.53) | 17.7 (2.0) | |||||
| > 20 to 30 | 321 (39.10) | 24.2 (1.2) | |||||
| >30 | 274 (33.37) | 53.2 (21.0) | |||||
| Chest (Gy) (yes) | 27 (1.72) | 46.7 (3.5) | 380 (29.40) | 36.7(25.7) | |||
| ≤ 35 | 13 (48.15) | 23.3 (9.7) | 243(63.95) | 23.1 (6.5) | |||
| > 35 | 14 (51.85) | 68.5 (35.2) | 137(36.04) | 61.1 (28.6) | |||
| Chemotherapy (mg/m2) | |||||||
| High-dose IV cytarabineb | 123 (7.85) | 16053 (12945) | 6 (0.46) | 25647 (18394) | |||
| Standard-dose IV cytarabine | 898 (57.31) | 6284 (5157) | 9 (0.70) | 1473 (720) | |||
| High-dose IV methotrexateb | 721 (46.01) | 14112 (9694) | 101 (7.82) | 86920 (40971) | |||
| Standard-dose IV methotrexate | 642 (40.97) | 2334 (1634) | 136 (10.53) | 278 (606) | |||
| Intrathecal methotrexate | 1156 (73.77) | 174 (112) | |||||
| IV Vincristine | 1256 (80.15) | 36 (27) | 716 (55.42) | 26 (19) | |||
| Anthracyclinec | 931 (59.41) | 158 (116) | 733 (56.73) | 243 (111) | |||
| Cyclophosphamided | 902 (57.56) | 9459 (6516) | 732 (56.66) | 10530 (7453) | |||
| Cisplatin | 55 (3.51) | 343 (216) | 153 (11.84) | 451 (205) | |||
| Corticosteroid (All) (Yes/No) | 1132 (72.24) | 249 (19.27) | |||||
| Neurosurgery (yes) | 370 (23.61) | ||||||
| Chronic Health Condition Severity/Burden Scoref | |||||||
| None/Low | 126 (8.0) | 88 (6.8) | |||||
| Medium | 762 (48.6) | 652 (50.5) | |||||
| High | 506 (32.3) | 425 (32.9) | |||||
| Very High | 173 (11.1) | 127 (9.8) | |||||
CNS: central nervous system; M(SD): mean and standard deviation; IV: intravenous; Gray empty cells are not applicable.
Acute myeloid leukemia, chronic myeloid leukemia, colon carcinoma, histiocytosis, germ cell tumors, liver malignancies, myelodysplastic syndrome, nasopharyngeal carcinoma, other carcinoma, other leukemia, and other malignancy,
high dose: 1g/m2 per treatment,
based on COG Long-Term Follow Up Guidelines 2018,
Green at al Pediatr Blood Cancer 2014 Jan; 6(61(1):53–67,
methylprednisolone, prednisolone, and prednisone,
Low: having only grade 1 conditions; Medium: having ≥1 grade 2 and/or 1 grade 3 condition; High: having ≥ 2 grade 3 conditions or 1 grade 4 and 1 grade 3 conditions; Very High: ≥2 grade 4 events or ≥ 2 grade 3 conditions and a grade 4 condition.